Published in Vaccine Weekly, September 7th, 1998
New data suggest that epitopes carried in the V3 loop of the HIV-1 envelope elicit antibodies. These antibodies don't seem to hurt HIV: but they attack and immobilize beta chemokines, the body's first-line defense against HIV infection.
"Our data indicate that anti-chemokine activities in the sera of HIV+ patients are due to a cross-reaction of anti-V3-loop antibodies with chemokines," noted Caner Susal and colleagues of the University of Heidelberg, Germany.
Susal reported the findings at the 12th World AIDS Conference, held June 28-July...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.